Edition:
United Kingdom

Medical Equipment, Supplies & Distribution

Page 1

Implanet announces CE mark clearance for JAZZ Passer

6:59am BST

Oct 19 (Reuters) - IMPLANET SA ::IMPLANET ANNOUNCES CE MARK CLEARANCE FOR JAZZ PASSER.

Amplitude Surgical FY EBITDA increases to 15.5 million euros

Wednesday, 18 Oct 2017

Oct 18 (Reuters) - AMPLITUDE SURGICAL SAS ::FY NET CASH POSTION EUR 41.6‍​ MILLION VERSUS EUR 32.1 MILLION YEAR AGO.FY ‍STRONG SALES GROWTH, IN LINE WITH MEDIUM-TERM TARGET: +16% TO EUR 93 MILLION​.FY EBITDA EUR ‍15.5​ MILLION VERSUS EUR 13.5 MILLION YEAR AGO.FY ATTRIBUTABLE NET LOSS EUR ‍​ 12.3 VERSUS LOSS OF EUR 174,000 YEAR AGO.FY CORE OPERATING PROFIT EUR ‍​17,000 VERSUS EUR 3.5 MILLION YEAR AGO.

BD statement on European Commission conditional clearance of Bard acquisition

Wednesday, 18 Oct 2017

Oct 18 (Reuters) - Becton Dickinson and Co :BD statement on European Commission conditional clearance of bard acquisition.Says continue to expect that BD and Bard transaction will close in fourth calendar quarter of 2017​.Says ‍"committed" to divesting certain assets to satisfy conditions requested by European Commission​ for Bard deal.

BD statement on European Commission conditional clearance of Bard acquisition

Wednesday, 18 Oct 2017

Oct 18 (Reuters) - Becton Dickinson and Co :BD statement on European Commission conditional clearance of bard acquisition.Says continue to expect that BD and Bard transaction will close in fourth calendar quarter of 2017​.Says ‍"committed" to divesting certain assets to satisfy conditions requested by European Commission​ for Bard deal.

Getinge Q3 core profit lags expectations, targets PPAC listing by year-end ​

Wednesday, 18 Oct 2017

Oct 18 (Reuters) - Getinge :Q3 ‍order intake increased by 2.2% to sek 7,334 m (7,176). Order intake increased organically by 4.7%.​.Getinge q3 - ‍net sales fell by 3.4% to sek 6,696 m (6,929). Net sales decreased organically by 0.7%.​.Q3 ‍ebita 1* declined by 31.6% to sek 659 m​.Getinge says organic sales growth is expected to be slightly positive in 2017.‍​.Getinge says currency transaction effects are expected to have a positive impact of approximately sek 250 m on getinge’s 2017 ebit‍​.Reuters poll: getinge q3 order intake was seen at 7.2 billion sek, adjusted. Ebita at 904 million.Says ‍net sales were adversely impacted by lower order intake in q2 and higher expenses partly related to work on preparing proposed distribution of patient & post-acute care business area​.Getinge says remainder of 2017 will be challenging, partly because the fourth quarter is our most important quarter in terms of sales and profitability, and partly because we have large-scale projects to complete before the start of 2018‍​.Getinge says aim is to distribute and list ppac division before end of year, on condition of a decision by the board and the approval of an extraordinary general meeting‍​.

Getinge sees 2017 organic growth in lower half of 0-2 pct guidance range - CEO

Wednesday, 18 Oct 2017

Oct 18 (Reuters) - Getinge Ab CEO Mattias Perjos in conference call with analysts and media: :says sees f/y 2017 organic sales growth in lower half of 0-2 percent guidance range.

Wuhan Thalys Medical Technology to pay H1 FY 2017 div

Wednesday, 18 Oct 2017

Oct 18(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says it will use additional paid-in capital to distribute 0.4 new shares for every share for H1 FY 2017, to shareholders of record on Oct. 20.Says the company's shares will be traded ex-right and ex-dividend on Oct. 23.

Biomerieux Q3 sales up at ‍​1.67 billion euros

Wednesday, 18 Oct 2017

Oct 18 (Reuters) - BIOMERIEUX SA ::Q3 SALES EUR ‍​1.67 BILLION VERSUS EUR 1.51 BILLION YEAR AGO.

Asit Biotech says active ingredients used in ASIT+ granted European patent

Tuesday, 17 Oct 2017

Oct 17 (Reuters) - ASIT BIOTECH SA ::ASIT BIOTECH ANNOUNCES THE GRANT OF A EUROPEAN PATENT ON THE ACTIVE INGREDIENTS USED IN THE ASIT+™ ALLERGY IMMUNOTHERAPY PRODUCT CANDIDATES.‍GRANT WILL BE EFFECTIVE FROM NOVEMBER 1, 2017 UNTIL JUNE 28, 2027 WITH A POSSIBLE EXTENSION OF 5 YEARS​.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary